公开(公告)号：US20220323409A1

公开(公告)日：2022-10-13

申请号：US17616460

申请日：2020-06-04

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Takumi ASADA ,  Gerald R. GALLUPPI ,  Seth Cabot HOPKINS ,  Megumi MARUYAMA ,  Siriporn TOONGSUWAN ,  Yuki TSUSHIMA

IPC: A61K31/40 ,  A61P25/18 ,  A61K9/20

Abstract: Provided are modified release compositions in a solid oral dosage form comprising racemic amisulpride, or pharmaceutically acceptable salts thereof, and medicaments comprising the same used for the treatment of various diseases and disorders, and methods of using same for the treatment of various diseases and disorders, including, but not limited to, dosage regimens.

公开(公告)号：US20200179336A1

公开(公告)日：2020-06-11

申请号：US16704202

申请日：2019-12-05

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Seth Cabot HOPKINS

IPC: A61K31/381 ,  A61P25/18

Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230241024A1

公开(公告)日：2023-08-03

申请号：US17933881

申请日：2022-09-21

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Linda Jane BRISTOW ,  Nina DEDIC ,  Eva HAJOS-KORCSOK ,  Seth Cabot HOPKINS ,  Philip Glyn JONES ,  Kenneth S. KOBLAN ,  Snezana MILANOVIC ,  Colleen Marie SYNAN ,  Kuangnan XIONG

IPC: A61K31/381 ,  A61P3/04 ,  A61P3/10 ,  A61P25/18 ,  A61K31/5513

CPC classification number: A61K31/381 ,  A61K31/5513 ,  A61P3/04 ,  A61P3/10 ,  A61P25/18

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders and diseases associated with metabolic disorders. For example, provided herein is Compound 1:





or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders associated with metabolic disorders.

公开(公告)号：US20240185965A1

公开(公告)日：2024-06-06

申请号：US18284130

申请日：2022-03-30

Applicant: SUNOVION PHARMACEUTICALS INC.

Inventor： Seth Cabot HOPKINS ,  Sasagu TOMIOKA

IPC: G16H10/20 ,  G16H20/70 ,  G16H50/20

CPC classification number: G16H10/20 ,  G16H20/70 ,  G16H50/20

Abstract: Clinical study populations require reduced heterogeneity to properly determine effectiveness of treatments. In an embodiment, a method of verifying eligibility of a subject for a treatment includes representing the subject's symptoms in a rating scale as a vector. The method computes an anomaly score based on the vector of the subject and multiple vectors representing rating scales of other subjects. The method ranks, based on the anomaly score, the subject with a likelihood of contributing to a subgroup of patients having a common element structure of the rating scale. The method enriches a study population in a clinical trial prior to randomization, the enriched study population having a reduced heterogeneity. Therefore, the method can verify diseases or conditions or diagnoses of subjects for eligibility for a clinical trial or for other purposes.

公开(公告)号：US20210315859A1

公开(公告)日：2021-10-14

申请号：US17228796

申请日：2021-04-13

Applicant: Sunovion Pharmaceuticals Inc.

Inventor： Carrie A. BOWEN ,  Seth Cabot HOPKINS ,  Colleen M. SYNAN

IPC: A61K31/381 ,  A61P25/18

Abstract: The present disclosure relates to methods of treating neurological or psychiatric diseases or disorders, such as schizophrenia. Compound 1, or a pharmaceutically acceptable salt thereof, is an antipsychotic agent with a non-D2 mechanism of action. Adverse events associated with antipsychotic agents that target the D2 dopamine receptor can be reduced by treating disorders with Compound 1, or a pharmaceutically acceptable salt thereof.